Study 33 of 36Semaglutide literaturebiorxiv-preprint · Observational2026

Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database

GLP-1 receptor agonists, including semaglutide, are associated with significant neuropsychiatric safety signals, warranting careful monitoring in clinical practice.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the semaglutide corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

This study evaluated neuro-adverse events associated with GLP-1 receptor agonists, including semaglutide, using FAERS and NHANES databases. The analysis identified significant neuro-adverse event signals, particularly highlighting muscle atrophy for semaglutide. The study also reported increased depression odds and reduced sleep hours among GLP-1RA users.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

ROR 3.94; 95%CI 3.42-4.54 for muscle atrophy with semaglutide.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Background: </h4> Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for type 2 diabetes and obesity, yet their neuropsychiatric safety profile remains incompletely characterized. We aimed to systematically evaluate neuro-adverse event (AE) signals for six GLP-1RAs and to validate key findings using population-based data. Methods We conducted disproportionality analysis of FAERS data for semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, and lixisenatide. RORs were calculated for 93 predefined neuro-AE MedDRA PTs across 11 neurological categories. External validation used NHANES 2013-2018 (n=17,057; 70 GLP-1RA users) with survey-weighted regression. Results We identified 41 significant neuro-AE signals. Semaglutide showed the strongest neuromuscular signal, muscle atrophy (ROR 3.94; 95%CI 3.42-4.54), corroborated by tirzepatide (ROR 2.35; 95%CI 2.04-2.71). Exenatide generated the highest psychiatric signal: nervousness (ROR 4.03; 95%CI 3.70-4.40). NHANES confirmed higher depression odds (OR 2.05; 95%CI 1.32-3.19; P=0.001) and reduced sleep hours (beta -0.35; P=0.033). Conclusions GLP-1RAs carry multiple neuropsychiatric safety signals, including muscle atrophy as a potential class effect and depression risk corroborated by population-level data. These findings support heightened clinical monitoring.

Elsewhere in the Semaglutide corpus

BMultimodal Strategies for Obesity Management: Integration and Combination of GLP-1/GIP Therapies, Bariatric Endoscopy, and Metabolic Surgery: A Scoping Reviewbiorxiv-preprint · 2026 · Not reported in abstract.Human BReal-World Insulin Deintensification and Discontinuation with GLP-1 Incretin Therapies Versus SGLT2 Inhibitors in Type 2 Diabetesbiorxiv-preprint · 2026 · 27.8% discontinued basal insulin with semaglutide vs 22.2% with SGLT2-i at 24 months, sHR 1.26, 95% CI 1.05–1.52, Gray P=0.013Human BCardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Studybiorxiv-preprint · 2026 · HR 0.80; 95% CI 0.69–0.92 for MACE at 12 months.Human BMapping Models of Tirzepatide Delivery for Obesity Management in Primary Care Settingsbiorxiv-preprint · 2026 · Not reported in abstract.Human BGlucagon-like peptide-1 receptor agonists and healthcare use in older adults with heart failure and obesitybiorxiv-preprint · 2026 · Adjusted risk ratio for all-cause inpatient utilization was 0.89 (95% CI: 0.84 – 0.93) for HF therapy + GLP-1 RA vs HF therapy.Human BEffect of Semaglutide on Recurrence of Intracranial Hypertension After Venous Sinus Stenting: A Two-Phase Cohort Studybiorxiv-preprint · 2026 · Semaglutide reduced IH recurrence compared to controls (5.9% vs 35.3%, P = 0.034).Human